Join
Live feed
·
PRReleasevia Quantisnow
Roivant Sciences Ltd. logo

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call

ByQuantisnow·Wall Street's wire, on your screen.
ROIV· Roivant Sciences Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ROIV (Roivant Sciences Ltd.) and more on Quantisnow.